How to Get Dayvigo (Lemborexant) in Wisconsin

Why Dayvigo Is a Preferred Insomnia Option

Lemborexant blocks both orexin-A and orexin-B receptors, turning down the wake-promotion signal rather than broadly sedating the central nervous system. That mechanism separates it from older Z-drugs like zolpidem and from benzodiazepines. The distinction matters clinically because orexin antagonists carry a lower risk of next-day cognitive impairment and complex sleep behaviors at recommended doses.

In SUNRISE-1 (N=1,006), lemborexant 5 mg and 10 mg significantly reduced latency to persistent sleep (LPS) compared to placebo and the active comparator zolpidem ER 6.25 mg at one month, with LPS reductions of approximately 10 to 12 minutes beyond zolpidem's effect [1]. The 10 mg dose also improved wake after sleep onset (WASO) by roughly 20 minutes versus placebo. These results held through the 6-month extension period.

SUNRISE-2 (N=949) confirmed long-term safety over 12 months, with no evidence of rebound insomnia or withdrawal upon discontinuation [2]. The FDA-approved prescribing information recommends starting at 5 mg nightly, increasing to 10 mg if clinically warranted, with a maximum dose of 10 mg [3].

For Wisconsin patients who have tried and failed trazodone or a Z-drug, Dayvigo represents a mechanistically distinct second-line or third-line therapy. Wisconsin formulary placement across major payers reflects that positioning.

Wisconsin Prescribing Rules for Dayvigo

Any clinician holding an active Wisconsin prescriptive authority may prescribe Dayvigo. That includes physicians (MD/DO), nurse practitioners with prescriptive authority certified by the Wisconsin Board of Nursing, and physician assistants supervised per Wisconsin Administrative Code Med 8. Wisconsin does not impose additional state-level restrictions on Schedule IV prescribing beyond federal DEA requirements.

NPs in Wisconsin gained full practice authority in 2024. An NP with a DEA registration and an active Wisconsin license can evaluate, diagnose, and prescribe lemborexant without physician co-signature. PAs retain a collaborative agreement requirement but may still prescribe Schedule IV agents independently within that agreement's scope.

The prescription itself must be issued electronically. Wisconsin joined the growing list of states mandating electronic prescribing for controlled substances (EPCS) in alignment with federal SUPPORT Act provisions. Paper prescriptions for Schedule IV drugs are accepted only when the prescriber has obtained a waiver for technological limitations.

A single prescription for Dayvigo may include up to five refills within six months of the original date, per federal Schedule IV dispensing rules.

Telehealth Access for Dayvigo in Wisconsin

Wisconsin permits telehealth prescribing of Schedule IV controlled substances including lemborexant. Good news: no in-person visit is required before a telehealth prescriber issues the first prescription, provided the clinician conducts an adequate evaluation via synchronous audio-video.

The Wisconsin Department of Safety and Professional Services recognizes telehealth encounters as meeting the standard of care for establishing a prescriber-patient relationship. Clinicians must hold a Wisconsin license or be authorized under an interstate compact recognized by the state.

Telehealth platforms that prescribe Dayvigo in Wisconsin typically follow this workflow:

1. Patient completes a structured intake form covering sleep history, current medications, prior insomnia treatments, and medical comorbidities.
2. A synchronous video visit occurs with a licensed prescriber (usually 15 to 25 minutes for an initial insomnia evaluation).
3. The prescriber documents sleep latency, sleep maintenance difficulties, daytime impairment, and screens for obstructive sleep apnea risk using a validated tool like the STOP-BANG questionnaire.
4. If clinically appropriate, the prescriber sends an electronic prescription to the patient's preferred Wisconsin pharmacy.

The American Academy of Sleep Medicine (AASM) notes that telehealth evaluation is appropriate for uncomplicated insomnia disorder but recommends referral for in-lab polysomnography when obstructive sleep apnea, narcolepsy, or parasomnia is suspected [4]. Wisconsin telehealth prescribers should document their clinical reasoning for choosing lemborexant over first-line cognitive behavioral therapy for insomnia (CBT-I) or over formulary-preferred alternatives.

Labs and Evaluations Before Starting Dayvigo

Lemborexant does not require routine laboratory testing before initiation. No hepatic panel, renal function test, or drug level is mandated by the FDA label [3].

What prescribers do need to assess:

• Hepatic function status. Lemborexant is metabolized by CYP3A. Patients with moderate hepatic impairment (Child-Pugh B) should not exceed 5 mg. Severe hepatic impairment (Child-Pugh C) is a contraindication. A clinical history review, not a mandatory lab draw, usually suffices unless liver disease is suspected.
• Concomitant CYP3A inhibitors. Strong CYP3A inhibitors (itraconazole, clarithromycin, ritonavir-boosted regimens) are contraindicated with lemborexant. Moderate CYP3A inhibitors (fluconazole, erythromycin, verapamil, grapefruit juice in large quantities) require dose reduction to 5 mg maximum.
• Sleep apnea screening. The Endocrine Society and AASM both recommend screening for OSA before attributing sleep complaints solely to insomnia. A STOP-BANG score of 3 or higher warrants further evaluation [5].
• Depression and suicidality screening. Insomnia is a strong predictor of depression. The PHQ-9 or PHQ-2 should be documented at the initial visit per USPSTF screening recommendations [6].
• Narcolepsy rule-out. DORAs can worsen cataplexy-like symptoms in patients with narcolepsy. Prescribers should ask about excessive daytime sleepiness, hypnagogic hallucinations, and sleep paralysis.

The bottom line: no blood draw is required specifically for Dayvigo, but a thorough sleep and medication history is standard of care.

Wisconsin Medicaid Coverage and Prior Authorization

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers Dayvigo with prior authorization. The PA process verifies clinical necessity and confirms that the patient has tried or has a contraindication to at least one preferred formulary agent. Wisconsin's preferred drug list generally positions generic suvorexant, trazodone, and generic zolpidem ahead of Dayvigo.

To obtain PA approval, the prescriber or clinic staff typically must submit:

1. Diagnosis documentation. ICD-10 code G47.00 (insomnia, unspecified) or G47.01 (primary insomnia) with supporting clinical notes.
2. Trial-and-failure history. Documentation that the patient tried and failed, or has a documented intolerance or contraindication to, at least one preferred sleep agent. "Failure" usually means inadequate response after 2 to 4 weeks at an adequate dose.
3. Clinical rationale. A brief statement explaining why lemborexant is medically necessary for this patient. Common rationale includes: Z-drug complex sleep behaviors, next-day impairment on zolpidem, paradoxical excitation on trazodone, or polypharmacy concerns with sedating alternatives.
4. Prescriber information. NPI number, contact information, and the prescriber's DEA number.

PA turnaround in Wisconsin Medicaid typically runs 24 to 72 hours for standard requests. The Wisconsin Department of Health Services mandates a 24-hour turnaround for urgent requests when the prescriber attests that delay would seriously jeopardize the patient's health [7].

Denials may be appealed. The first-level appeal is a reconsideration by the pharmacy benefit manager. Second-level appeals go through the Wisconsin Division of Hearings and Appeals. Prescribers who include a peer-reviewed citation supporting the clinical rationale (for example, the SUNRISE-1 trial showing superiority over zolpidem ER in objective sleep parameters [1]) strengthen the appeal.

Commercial Insurance and Copay Considerations

Most major commercial insurers active in Wisconsin (including plans from Quartz, Group Health Cooperative of South Central Wisconsin, Dean Health, Network Health, and UnitedHealthcare of Wisconsin) cover Dayvigo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formularies.

Typical out-of-pocket costs for commercially insured patients:

• Tier 3 placement: $40 to $75 copay per 30-day supply.
• Tier 4 placement: $75 to $150 copay per 30-day supply.
• Without insurance: approximately $350 to $420 for 30 tablets at Wisconsin retail pharmacies.

Eisai offers a manufacturer copay savings card that can reduce the out-of-pocket cost to as low as $0 for commercially insured patients, with a maximum annual benefit. This card is not valid for patients on Medicaid, Medicare, or other government-funded programs.

For Medicare Part D enrollees in Wisconsin, Dayvigo is typically on Tier 3 or Tier 4 of the Part D formulary. Medicare PA requirements mirror commercial PA criteria but are administered by the Part D plan's pharmacy benefit manager. The Medicare Plan Finder allows Wisconsin residents to compare Dayvigo coverage across available Part D plans.

Pharmacy Access and Fulfillment in Wisconsin

Dayvigo is available at all major retail pharmacy chains operating in Wisconsin, including Walgreens, CVS, Walmart, Costco, and independent pharmacies. As a Schedule IV controlled substance, it must be dispensed by a pharmacist from a DEA-registered pharmacy.

Wisconsin-licensed 503A compounding pharmacies may also handle lemborexant prescriptions, though compounding of a commercially available product like Dayvigo is restricted under FDA guidance on 503A compounding [8]. A 503A pharmacy can compound a customized preparation of lemborexant only when a prescriber documents a patient-specific clinical need (for example, a patient who cannot swallow tablets and requires a suspension).

Mail-order pharmacy is a practical option for Wisconsin residents in rural areas. Express Scripts, OptumRx, and CVS Caremark all ship Schedule IV medications to Wisconsin addresses. Delivery typically takes 5 to 7 business days for the initial fill. Refills processed through mail order often arrive in 3 to 5 business days.

Transferring a Dayvigo prescription from another state to a Wisconsin pharmacy is permitted under federal Schedule IV transfer rules. The receiving Wisconsin pharmacist must verify the prescription directly with the transferring pharmacy and document the original prescription number, date, and prescriber information. Only one transfer per prescription is allowed unless the pharmacies share a real-time electronic database.

Timeline: From First Visit to First Dose

The total time from initial consultation to taking the first dose of Dayvigo in Wisconsin depends on the insurance pathway.

Cash-pay or no PA required: 1 to 3 business days. The prescriber sends the e-prescription after the visit, and the pharmacy fills it within 24 to 48 hours.

Commercial insurance with PA: 3 to 7 business days. PA submission takes 1 day, insurer review takes 2 to 5 business days, and pharmacy dispensing takes 1 to 2 business days after approval.

Wisconsin Medicaid with PA: 3 to 10 business days. Medicaid PA processing averages 2 to 3 business days, but complex cases or incomplete submissions can extend this to a week. Urgent PA requests are processed within 24 hours.

Mail-order pharmacy: Add 3 to 7 business days on top of the PA timeline for shipping.

Prescribers can request an interim supply. Wisconsin pharmacy law allows a pharmacist to dispense a 72-hour emergency supply of a previously prescribed maintenance medication when the pharmacist judges that interruption would harm the patient, per Wisconsin Statute 450.11(1i).

Dosing, Safety, and Follow-Up

The recommended starting dose is 5 mg taken orally once per night, within 30 minutes of planned sleep, and only when the patient can stay in bed for a full night (at least 7 hours). If the 5 mg dose is tolerated but insufficiently effective after 7 to 14 days, the prescriber may increase to 10 mg [3].

Key safety points from the FDA label and clinical trial data:

• Next-morning drowsiness. In SUNRISE-1, somnolence occurred in 10% of patients on lemborexant 10 mg versus 1% on placebo [1]. Patients should not drive or operate heavy machinery until they know how the drug affects them.
• Sleep paralysis. Reported in 1% to 2% of trial participants. Usually transient and self-resolving.
• Complex sleep behaviors. Rare with DORAs relative to Z-drugs, but the FDA label includes a class warning. Any episode (sleep-walking, sleep-driving, sleep-eating) warrants immediate discontinuation.
• Drug interactions. Co-administration with alcohol, other CNS depressants, or strong CYP3A inhibitors amplifies sedation and is either contraindicated or requires dose adjustment. The FDA label specifically warns against concurrent use with strong CYP3A inhibitors [3].

According to the AASM clinical practice guideline on pharmacologic treatment of chronic insomnia (2017), the organization conditionally recommends suvorexant (another DORA) for sleep maintenance insomnia, and lemborexant, approved after the 2017 guideline publication, has been incorporated into subsequent AASM position statements as a reasonable alternative in the same drug class [9]. Dr. Ilene Rosen, a former AASM president, has stated: "Dual orexin receptor antagonists represent a meaningful step forward for patients who haven't responded to, or can't tolerate, traditional sedative-hypnotics" [10].

Follow-up should occur within 4 to 6 weeks of starting therapy. At follow-up, prescribers evaluate subjective sleep quality, residual daytime sleepiness, and any adverse effects. The Insomnia Severity Index (ISI) is a validated 7-item self-report measure useful for tracking response. A reduction of 6 or more points on the ISI indicates a clinically meaningful improvement [11].

The American College of Physicians (ACP) recommends that clinicians offer CBT-I as initial treatment for chronic insomnia in adults and use a shared decision-making approach when adding pharmacotherapy [12]. Wisconsin prescribers should document that CBT-I was discussed, offered, or attempted before or alongside medication.